BULK-DATA-CENTERS
30.11.2021 08:07:05 CET | Business Wire | Press release
DE-CIX , the world’s leading Internet Exchange (IX) operator and home to the largest carrier and data center neutral interconnection ecosystem globally, today announces its expansion to the Nordic region. DE-CIX has partnered with Bulk Data Centers , which will house DE-CIX IX platforms in Oslo, Norway (OS-IX), Kristiansand, Norway (Campus N01), as well as in Esbjerg, Denmark (Campus DK01). DE-CIX will also be opening IX platforms in Finland.
DE-CIX’s expansion into the Nordic region will open the Nordics to international customers, providing 100 percent green-powered Internet Exchanges through Bulk’s data centers. In addition, local Nordic customers will now get faster and more efficient access to global internet exchange services.
“The Nordic region comprises some of the world’s most highly developed digital markets,” says Ivo Ivanov, CEO of DE-CIX International, on the company’s expansion to Northern Europe. “However, the interconnection infrastructure available in the region does not match the digital maturity of the economy in the Nordics. DE-CIX has seen strong support from the Nordic data center community for our plans to expand to the region, in which we will localize our interconnection capabilities for these markets, at the same time as integrating them into the DE-CIX European and trans-continental interconnection ecosystem,” Ivanov explains.
For the market entry into the Nordics, Bulk Data Centers, a part of Bulk Infrastructure Group, will be the initial partner supporting DE-CIX from Day 1. Bulk Infrastructure is Norway’s leader in building and operating sustainable digital infrastructure, data center, colocation, fiber network and industrial real estate. The DE-CIX interconnection platforms will be available in the Bulk data centers in Oslo (OS-IX) and Kristiansand (Campus N01) (Norway), as well as Esbjerg (Campus DK01) (Denmark).
“This partnership with DE-CIX will further enhance the options for customers to interconnect and access a range of services in addition to the already low latency access to major markets combined with the greenest cheapest energy in Europe,” says Gisle M. Eckhoff, Executive Vice President Data Centers at Bulk Infrastructure. “We are seeing an increase in demand for low cost, highly sustainable solutions and with these new DE-CIX Nordics locations we are helping to support that gravity shift North. We are delighted to build on our previous investments to unlock the potential of the Nordics and look forward to working with DE-CIX to enable more customers to take advantage of renewable, long term sustainable data centers.”
The Internet Exchange operator’s expansion to Norway, Denmark and Finland will serve the regional connectivity needs, boosted by new transatlantic and intercontinental submarine cables bridging the Nordics with North America and Asia. DE-CIX will fully integrate the Nordic exchanges into the company’s existing leading carrier and data center neutral interconnection ecosystem – the largest such in not only Central and Southern Europe, consisting of more than 10 IXs (2100+ connected networks), but also North America, with currently 5 IXs (400+ connected networks).
The new DE-CIX Internet Exchanges in the Nordics will have presences in all relevant data center facilities in the respective markets.
With the new DE-CIX IX platforms in Norway, Denmark and Finland, the company is extending its global footprint to overall 32 locations in Europe, North America, the Middle East, and Asia. The combined connected customer capacity of all DE-CIX locations worldwide exceeds 85 Terabits, making it the largest neutral interconnection ecosystem in the world.
About Bulk Data Centers
Bulk Data Centers delivers resiliency, cost efficiency, scalability and sustainability without compromise and with a dedication to personalized service excellence. As a trusted advisor offering strategically located Nordic data centers, Bulk enables customers to reduce costs and environmental impact while supporting data with highly connected, 100 percent green-powered and ultra-flexible colocation, white space, build-to-suit data center solutions and powered land. Backed by decades of expertise, Bulk delivers turnkey digital infrastructure that takes the sustainability and business value of the Nordic data center to the next level.
About DE-CIX
DE-CIX (German Commercial Internet Exchange) is the world’s leading operator of Internet Exchanges. In total, in its 32 locations in Europe, North America, the Middle East, and Asia, DE-CIX interconnects over 2400 network operators (carriers), Internet service providers (ISPs), content providers, and enterprise networks from more than 100 countries, offering peering, cloud, and interconnection services. The combined connected customer capacity of all DE-CIX locations worldwide exceeds 85 Terabits, making it the largest neutral interconnection ecosystem in the world. DE-CIX in Frankfurt, Germany, with a data throughput of more than 10 Terabits per second (Tbps) and over 1000 connected networks, is one of the largest Internet Exchanges in the world.
Further information at www.de-cix.net
View source version on businesswire.com: https://www.businesswire.com/news/home/20211129005723/en/
Link:
Social Media:
https://www.facebook.com/DECIX.Internet.Exchange/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
